Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15191550 | 1.00 | HTT (0.37) | HTTMCL1MEN1KMT2ATAS1R3 | |
| SCHEMBL1935629 | 0.94 | MCL1 (0.42) | HTTMCL1KMT2ANPC1LMNA | |
| SCHEMBL2792237 | 0.94 | MCL1 (0.42) | HTTMCL1KMT2ANPC1LMNA | |
| SCHEMBL19246194 | 0.81 | KDM4E (0.40) | HTTLMNA | |
| SCHEMBL12270404 | 0.81 | KDM4E (0.40) | HTTLMNA | |
| SCHEMBL12341652 | 0.79 | CCR2 (0.49) | HTTKMT2ASMN1; SMN2ALDH1A1CCR2 | |
| SCHEMBL12273703 | 0.78 | CCR2 (0.56) | HTTKMT2ASMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL19538734 | 0.78 | CCR2 (0.51) | KMT2ASMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL21006304 | 0.78 | CCR2 (0.56) | HTTKMT2ASMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL19538733 | 0.78 | CCR2 (0.51) | KMT2ASMN1; SMN2ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-3956031-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | Pfizer Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-2766350-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3057957-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| EP-2766350-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Eli Lilly and Company (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8658693-B2 | 4-aminobenzonitrile selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130217762-A1 | Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013055577-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | HTT 2799/4885MCL1 3570/4885MEN1 1145/4885 |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | HTT 2874/4885MCL1 471/4885MEN1 368/4885 |
| US-20130217762-A1 | Selective Androgen Receptor Modulators | AR, NR5A1, ESRRA | HTT 4219/4885MCL1 3870/4885MEN1 3752/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | HTT 21/4885MCL1 3594/4885MEN1 1038/4885 |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | HTT 1743/4885MCL1 4032/4885MEN1 2014/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | HTT 2874/4885MCL1 471/4885MEN1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.